BGT226
BGT226 (NVP-BGT226) is a PI3K (with IC50s of 4 nM, 63 nM and 38 nM for PI3Kα, PI3Kβ and PI3Kγ) /mTOR dual inhibitor which displays potent growth-inhibitory activity against human head and neck cancer cells[1][2].
Product Specifications
CAS Number
915020-55-2
Product Name Alternative
NVP-BGT226
UNSPSC
12352005
Target
Autophagy; mTOR; PI3K
Type
Reference compound
Related Pathways
Autophagy; PI3K/Akt/mTOR
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/BGT226.html
Purity
99.85
Solubility
DMSO : 10 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C(N1C2=CC=C(N3CCNCC3)C(C(F)(F)F)=C2)N(C)C4=C1C5=CC(C6=CC=C(OC)N=C6)=CC=C5N=C4
Molecular Formula
C28H25F3N6O2
Molecular Weight
534.53
References & Citations
[1]Markman B, et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors. Ann Oncol. 2012 Sep;23 (9) :2399-408.|[2]Chang KY, et al. Novel phosphoinositide 3-kinase/mTOR dual inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo. Clin Cancer Res. 2011 Nov 15;17 (22) :7116-26.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
MTOR; PI3Kα; PI3Kβ; PI3Kγ
Citation 01
Molecules. 2020 Apr 23;25 (8) :1980.|Arch Pharm (Weinheim) . 2024 Sep;357 (9) :e2400066.|Front Pharmacol. 2020 Nov 11;11:580407.|Harvard Medical School LINCS LIBRARY|Research Square Print. 2023 Mar 9.|Sci Transl Med. 2018 Jul 18;10 (450) :eaaq1093.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
